77 related articles for article (PubMed ID: 37559984)
1. Gastric cancer with enhanced myogenesis is associated with less cell proliferation, enriched epithelial-to-mesenchymal transition and angiogenesis, and poor clinical outcomes.
Chida K; Oshi M; An N; Kanazawa H; Roy AM; Mann GK; Yan L; Endo I; Hakamada K; Takabe K
Am J Cancer Res; 2024; 14(1):355-367. PubMed ID: 38323295
[TBL] [Abstract][Full Text] [Related]
2.
Oshi M; Ziazadeh D; Wu R; Chida K; Yamada A; Yamamoto S; Narui K; Yan L; Ishikawa T; Endo I; Takabe K
Cancers (Basel); 2023 Jul; 15(13):. PubMed ID: 37444599
[TBL] [Abstract][Full Text] [Related]
3. The effects of restricted glycolysis on stem-cell like characteristics of breast cancer cells.
Banerjee A; Arvinrad P; Darley M; Laversin SA; Parker R; Rose-Zerilli MJJ; Townsend PA; Cutress RI; Beers SA; Houghton FD; Birts CN; Blaydes JP
Oncotarget; 2018 May; 9(33):23274-23288. PubMed ID: 29796188
[TBL] [Abstract][Full Text] [Related]
4. High miR-200c expression is associated with suppressed epithelial-mesenchymal transition, TGF-β signaling and better survival despite enhanced cell proliferation in gastric cancer patients.
Shichiri K; Oshi M; Ziazadeh D; Endo I; Takabe K
Am J Cancer Res; 2023; 13(7):3027-3040. PubMed ID: 37560006
[TBL] [Abstract][Full Text] [Related]
5. Mettl3 synergistically regulates TGF-β/SMAD2/3 to promote proliferation and metastasis of gastric cancer.
Yuan XN; Liu Q; Shao YC; Guan XQ; Yang ZL; Chu MF; Zhang JW; Tian YH; Wei L
Am J Cancer Res; 2023; 13(7):3185-3202. PubMed ID: 37560008
[TBL] [Abstract][Full Text] [Related]
6. CD133 expression is associated with less DNA repair, better response to chemotherapy and survival in ER-positive/HER2-negative breast cancer.
Sato T; Oshi M; Huang JL; Chida K; Roy AM; Endo I; Takabe K
Res Sq; 2024 Mar; ():. PubMed ID: 38585981
[TBL] [Abstract][Full Text] [Related]
7. The movement of mitochondria in breast cancer: internal motility and intercellular transfer of mitochondria.
Libring S; Berestesky ED; Reinhart-King CA
Clin Exp Metastasis; 2024 Mar; ():. PubMed ID: 38489056
[TBL] [Abstract][Full Text] [Related]
8. Higher Inflammatory Response in Hepatocellular Carcinoma is Associated with Immune Cell Infiltration and a Better Outcome.
Oshi M; Chida K; Roy AM; Mann GK; An N; Yan L; Endo I; Takabe K
Res Sq; 2024 Jan; ():. PubMed ID: 38260290
[TBL] [Abstract][Full Text] [Related]
9. Metabolic Reprogramming in Triple-Negative Breast Cancer.
Sun X; Wang M; Wang M; Yu X; Guo J; Sun T; Li X; Yao L; Dong H; Xu Y
Front Oncol; 2020; 10():428. PubMed ID: 32296646
[TBL] [Abstract][Full Text] [Related]
10. Correlation between the Warburg effect and progression of triple-negative breast cancer.
Liu S; Li Y; Yuan M; Song Q; Liu M
Front Oncol; 2022; 12():1060495. PubMed ID: 36776368
[TBL] [Abstract][Full Text] [Related]
11. Accelerated glycolysis in tumor microenvironment is associated with worse survival in triple-negative but not consistently with ER+/HER2- breast cancer.
Oshi M; Roy AM; Yan L; Sasamoto M; Tokumaru Y; Wu R; Yamada A; Yamamoto S; Chishima T; Narui K; Endo I; Takabe K
Am J Cancer Res; 2023; 13(7):3041-3054. PubMed ID: 37559984
[TBL] [Abstract][Full Text] [Related]
12. The clinical relevance of unfolded protein response signaling in breast cancer.
Oshi M; Roy AM; Gandhi S; Tokumaru Y; Yan L; Yamada A; Endo I; Takabe K
Am J Cancer Res; 2022; 12(6):2627-2640. PubMed ID: 35812054
[TBL] [Abstract][Full Text] [Related]
13. A novel five-gene score to predict complete pathological response to neoadjuvant chemotherapy in ER-positive/HER2-negative breast cancer.
Oshi M; Gandhi S; Angarita FA; Kim TH; Tokumaru Y; Yan L; Matsuyama R; Endo I; Takabe K
Am J Cancer Res; 2021; 11(7):3611-3627. PubMed ID: 34354863
[TBL] [Abstract][Full Text] [Related]
14. Abundance of reactive oxygen species (ROS) is associated with tumor aggressiveness, immune response, and worse survival in breast cancer.
Oshi M; Gandhi S; Yan L; Tokumaru Y; Wu R; Yamada A; Matsuyama R; Endo I; Takabe K
Breast Cancer Res Treat; 2022 Jul; 194(2):231-241. PubMed ID: 35639264
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
